C.R. Bard (BCR) : $27.31 million worth of transactions were on upticks in C.R. Bard (BCR), compared to $20.37 million on downticks. The ratio between the two was 1.34, whereas, the net money flow stood at a healthy $6.95 million on Wednesdays session. The consistent buying on upticks in the stock accounted for $8.28million worth of trades. The total money flow into the stock stood at $8.28 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.56%. The stock was trading at $227.3, with a drop of $1.29 over the previous days close. The stock recorded -1.14% for the week.
CR Bard Inc. has dropped 0.53% in the last five trading days, however, the shares have posted positive gains of 3.14% in the last 4 weeks. CR Bard Inc. has dropped 2.06% during the last 3-month period . Year-to-Date the stock performance stands at 20.42%.
C.R. Bard (BCR) : The consensus on C.R. Bard (BCR) based on 14 analyst recommendation on the company stock is 2.64, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 11 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
C.R. Bard (NYSE:BCR): stock was range-bound between the intraday low of $226.32 and the intraday high of $228.86 after having opened at $228.56 on Wednesdays session. The stock finally closed in the red at $228.56, a loss of -0.56%. The stock remained in the red for the whole trading day. The total traded volume was 459,703 shares. The stock failed to cross $228.86 in Wednesdays trading. The stocks closing price on Thursday was $228.59.
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.